Table 1.
Study | Differentiation method | Modelled disease | Some achievements |
---|---|---|---|
84 | MyoD transfection | Facioscapulohumeral muscular dystrophy | Generation of isogenic control clones. Gene correction (CRISPR/Cas9) |
85 | MyoD transfection | Duchenne muscular dystrophy | Evaluation of exon skipping in disease‐specific myocytes |
72 | Small molecules | Pompe disease | Gene correction (CRISPR/Cas9) Large‐scale expansion |
71 | Pax7 transfection | Myotonic dystrophy 1 | NA |
86 | Small molecules | Duchenne muscular dystrophy | Generation of transplantable myogenic cells |
87 | MyoD transfection | Muscular dystrophy | High‐throughput drug screening |
88 | MyoD transfection | Infantile‐onset Pompe disease | NA |
89 | MyoD transfection | Limb girdle muscular dystrophy type 2C | iPSCs derived from urine cells Gene correction (CRISPR/Cas9) |
90 | MyoD transfection | Amyotrophic lateral sclerosis | Study of neuromuscular microenvironment and generation of functional myotubes |
NA, not applicable.